Please ensure Javascript is enabled for purposes of website accessibility

Why Aphria, Curaleaf, and Several Other Cannabis Stocks Are Flying Higher Today

By Keith Speights – Oct 8, 2020 at 1:54PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors appear to be increasingly optimistic about the prospects for marijuana legalization in the U.S. after two developments on Wednesday.

What happened

Several cannabis stocks were flying higher on Thursday. Aphria (APHA) had the biggest gains, with its shares up 8.8% as of 11:41 a.m. EDT. OrganiGram's (OGI -3.36%) shares jumped 7.1%.

It wasn't just Canadian cannabis stocks that enjoyed solid gains, though. Shares of U.S.-based Curaleaf Holdings (CURLF 4.41%) were also up 8.8%. Green Thumb Industries (GTBIF 1.07%) and Charlotte's Web Holdings (CWBHF 1.47%) weren't too far behind, with gains of 7.9% and 6.6%, respectively.

There are two likely reasons for these moves today. In the vice-presidential debate Wednesday night, Democratic vice presidential candidate Sen. Kamala Harris promised that a potential Biden administration would decriminalize marijuana. Also, Vermont became the 11th state to legalize recreational marijuana on Wednesday.

Cannabis with line trending upward and money in the background

Image source: Getty Images.

So what

Neither Sen. Harris' comments nor Vermont's recreational marijuana legalization will do anything to boost any of these cannabis stocks' immediate prospects. Even if Democratic presidential nominee Joe Biden and Harris win the election next month, they won't take office until January 2021. Vermont isn't expected to open its recreational pot market until October 2022.

However, investors' sentiment is important for stocks. And it appears that many investors are more optimistic about the cannabis industry and, in particular, the possibility of movement toward the legalization of cannabis at the federal level in the U.S.

U.S.-based cannabis companies would be the biggest beneficiaries if federal marijuana laws are changed. Curaleaf and Green Thumb, for example, currently can't list their shares on major U.S. stock exchanges. Their shares would almost certainly soar if the companies could operate in full compliance with all federal laws.

Canadian cannabis producers such as Aphria and OrganiGram could also be winners if U.S. marijuana laws are revised. The companies can't operate in the U.S. marijuana market right now and retain their listings on U.S. stock exchanges.

Charlotte's Web is perhaps the most surprising big riser today. The company sells hemp-based products. Hemp is already legal at the federal level in the U.S. However, Charlotte's Web is often categorized as a marijuana stock -- and a rising tide tends to lift all boats.

Now what

The countdown is on for the U.S. elections on Nov. 3. Perhaps the most important races for investors to watch are in the Senate. If the Democrats regain control of the Senate and retain a majority in the House of Representatives (as they're expected to do), the prospects of federal marijuana reform will be much brighter than they are now.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Green Thumb Industries and OrganiGram Holdings. The Motley Fool recommends Charlotte's Web. The Motley Fool has a disclosure policy.

Stocks Mentioned

OrganiGram Stock Quote
$1.15 (-3.36%) $0.04
Green Thumb Industries Stock Quote
Green Thumb Industries
$15.63 (1.07%) $0.17
Charlotte's Web Stock Quote
Charlotte's Web
$0.67 (1.47%) $0.01
Curaleaf Stock Quote
$7.57 (4.41%) $0.32
Aphria Inc. Stock Quote
Aphria Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.